Review of best treatment option in heart failure 2023

Gerardo Garcia Santiago; Andrea Marin Gomez; Guillermo Avalos Gonzalez; Oscar Jesus Leal Ramos; Alejandra Arias Castro; Mariano Belisario López Pere

doi:10.18203/2349-3933.ijam20233512

Authors

Gerardo Garcia Santiago Department of Academic Unit of Health Sciences, Universidad Autonoma de Guadalajara, Guadalajara, Jalisco, Mexico https://orcid.org/0009-0009-9135-400X
Andrea Marin Gomez Department of Academic Unit of Health Sciences, Universidad Autonoma de Guadalajara, Guadalajara, Jalisco, Mexico
Guillermo Avalos Gonzalez Department of Academic Unit of Health Sciences, Universidad Autonoma de Guadalajara, Guadalajara, Jalisco, Mexico
Oscar Jesus Leal Ramos Department of Internal Medicine, Mexican Social Security Institute, Guadalajara, Jalisco, Mexico
Alejandra Arias Castro Department of Academic Unit of Health Sciences, Universidad Autonoma de Guadalajara, Guadalajara, Jalisco, Mexico
Mariano Belisario López Pere Department of Academic Unit of Health Sciences, Universidad Autonoma de Guadalajara, Guadalajara, Jalisco, Mexico

DOI:

https://doi.org/10.18203/2349-3933.ijam20233512

Keywords:

SLGT2, ARNIs, Heart failure, Progression, Treatment

Abstract

Congestive heart failure is a clinical condition in which the heart is unable to pump enough blood to meet the metabolic needs of the body because of pathological changes in the myocardium. The three main causes of CHF are coronary artery disease, diabetes mellitus, and hypertension. US hospitalizations for heart failure decreased up until 2012; however, from 2013 to 2017, an increase in HF hospitalizations was observed. In 2017, there were 1.2 million HF hospitalizations in the United States among 924 000 patients with HF. This represents a 26% increase in HF hospitalizations and number of patients hospitalized with HF. For this reason, as a team, we have decided to conduct a review of the best treatment options for heart failure based on multiple articles.

References

Heidenreich PA, Bozkurt B, Aguilar D. AHA/ACC/HFSA guideline for the management of heart failure: a report of the american college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022; 145(18):E895-1032.

Bahrami H, Kronmal R, Bluemke DA. Differences in the Incidence of Congestive Heart Failure by Ethnicity: The Multi-Ethnic Study of Atherosclerosis. Arch Intern Med. 2008;168(19):2138-45.

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624.

Kasper DL, Fauci AS, Hauser S, Longo D, Jameson LJ, Loscalzo J. Harrisons Principles of Internal Medicine. USA: McGraw-Hill Medical Publishing Division; 2016.

Yancy CW, Jessup M, Bozkurt B. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776-803.

Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121(3):951-7.

McDowell K, Petrie MC, Raihan NA, Logue J. Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obesity Rev. 2018; 19(9):1189-204.

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron Deficiency in Heart Failure: An Overview. JACC Heart Fail. 2019;7(1):36-46.